HRP20150400T1 - Lijeäśenje pedijatrijske akutne limfoblastiäśne leukemije - Google Patents
Lijeäśenje pedijatrijske akutne limfoblastiäśne leukemije Download PDFInfo
- Publication number
- HRP20150400T1 HRP20150400T1 HRP20150400TT HRP20150400T HRP20150400T1 HR P20150400 T1 HRP20150400 T1 HR P20150400T1 HR P20150400T T HRP20150400T T HR P20150400TT HR P20150400 T HRP20150400 T HR P20150400T HR P20150400 T1 HRP20150400 T1 HR P20150400T1
- Authority
- HR
- Croatia
- Prior art keywords
- construct
- accordance
- intended
- chain antibody
- bispecific single
- Prior art date
Links
- 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 title claims 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 12
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 11
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 11
- 208000007660 Residual Neoplasm Diseases 0.000 claims 6
- 230000000735 allogeneic effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000008030 elimination Effects 0.000 claims 2
- 238000003379 elimination reaction Methods 0.000 claims 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 2
- 230000000116 mitigating effect Effects 0.000 claims 2
- 230000008707 rearrangement Effects 0.000 claims 2
- 238000011476 stem cell transplantation Methods 0.000 claims 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 1
- 208000031404 Chromosome Aberrations Diseases 0.000 claims 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 claims 1
- 208000008691 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 108700019889 TEL-AML1 fusion Proteins 0.000 claims 1
- 208000037280 Trisomy Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 238000000638 solvent extraction Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Claims (19)
1. CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt, naznačeno time što je namijenjeno upotrebi u postupku liječenja, ublažavanja ili otklanjanja pedijatrijske akutne limfoblastične leukemije (ALL) kod pedijatrijskog pacijenta s ALL.
2. Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je navedena pedijatrijska akutna limfoblastična leukemija (ALL) pedijatrijska akutna limfoblastična leukemija (ALL) B-loze, po mogućnosti pedijatrijska akutna limfoblastična leukemija ALL preteča B-stanica, poželjnije pedijatrijska pro-B ALL, pre-B ALL ili zajednička ALL (cALL).
3. Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je navedena akutna limfoblastična leukemija (ALL) refrakterna i/ili recidiv ALL.
4. Konstrukt namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je postupak namijenjen liječenju, ublažavanju ili otklanjanju minimalne preostale bolesti (MRD) kod pedijatrijskog pacijenta s ALL.
5. Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što je navedeni pedijatrijski pacijent s ALL pozitivnom na MRD kod potpunog hematološkog povlačenja.
6. Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 4 ili 5, naznačen time što se MRD mjeri kvantitativnim opažanjem najmanje jedne od citogenetičkih abnormalnosti ili pregradnji, koje se bira iz skupine koju čine:
t(12;21)[TEL-AML1];
t(1;19)[E2A-PBX];
t(4;11)[AF4-MLL];
t(9;22)[BCR-ABL];
hiperdiploidnost ili trisomije kromosoma 4, 10 i 17;
hipodiploidnost;
pregradnje imunoglobulinskih gena; i
pregradnje receptora T-stanica (TCR).
7. Konstrukt namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što su odgovarajuća varijabilna područja teškog lanca (VH) i odgovarajuća varijabilna područja lakog lanca (VL) u navedenom CD19xCD3 bispecifičnom jednolančanom protutijelu kao konstruktu posložena, od N-kraja do C-kraja, ovim redoslijedom: VL(CD19)-VH(CD19)-VH(CD3)-VL(CD3).
8. Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što navedeno CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt ima aminokiselinski slijed kako što je iznijet u SEQ ID NO. 1, ili aminokiselinski slijed koji je najmanje 90%, po mogućnosti 95%, istovjetan sa SEQ ID NO. 1.
9. Konstrukt namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što farmaceutski pripravak koji sadrži CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt treba primjenjivati kontinuiranom infuzijom najmanje četiri tjedna, za čim slijedi dvotjedni interval bez liječenja.
10. Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što navedenu primjenu treba ponoviti najmanje dva, tri, četiri, pet, šest, sedam, osam, devet ili deset puta, nakon što se odredi status negativnosti na MRD.
11. Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 9 ili 10, naznačen time što se postupak provodi prije alogenog presađivanja matičnih stanica (HSCT) kako bi se promijenilo ALL pozitivnu na MRD u status negativnosti na MRD.
12. Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 9 ili 10, naznačen time što se postupak provodi nakon alogenog presađivanja krvotvornih matičnih stanica (HSCT).
13. Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt potiče učinak presatka prema leukemiji (GvL).
14. Konstrukt namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt treba primijeniti u dnevnoj dozi od 10 µg do 100 µg/m2 tjelesne površine pacijenta.
15. Konstrukt namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt treba primijeniti u dnevnoj dozi od 15 µg do 30 µg/m2 tjelesne površine pacijenta.
16. Konstrukt namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt treba primijeniti u dnevnoj dozi od 15 µg, 30 µg, 60 µg ili 90 µg/m2 tjelesne površine pacijenta.
17. Konstrukt namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt prvog ili prvih dana treba primijeniti u dozi od 5 µg, sljedećeg ili sljedećih dana u dozi od 15 µg, a preostali period primjene od ukupno 4 tjedna u dozi od 30 ili 45 µg/m2 tjelesne površine pacijenta kao dnevnoj dozi.
18. Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 17, naznačen time što se dvije početne doze primjenjuje 2, 3, 4, 5, 6 ili 7 dana ili čak i dulje.
19. Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što navedeni pacijent nije prikladan za alogeno presađivanje matičnih stanica.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11232308P | 2008-11-07 | 2008-11-07 | |
| US18329109P | 2009-06-02 | 2009-06-02 | |
| US22126909P | 2009-06-29 | 2009-06-29 | |
| PCT/EP2009/007969 WO2010052013A1 (en) | 2008-11-07 | 2009-11-06 | Treatment of pediatric acute lymphoblastic leukemia |
| EP09764710.1A EP2344539B1 (en) | 2008-11-07 | 2009-11-06 | Treatment of pediatric acute lymphoblastic leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150400T1 true HRP20150400T1 (hr) | 2015-05-08 |
Family
ID=41796119
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150400TT HRP20150400T1 (hr) | 2008-11-07 | 2015-04-10 | Lijeäśenje pedijatrijske akutne limfoblastiäśne leukemije |
| HRP20180426TT HRP20180426T1 (hr) | 2008-11-07 | 2018-03-12 | Liječenje pedijatrijske akutne limfoblastične leukemije |
| HRP20191715 HRP20191715T1 (hr) | 2008-11-07 | 2019-09-20 | Liječenje dječje akutne limfoblastične leukemije sa bispecifičnim protutijelima protiv cd3xcd19 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180426TT HRP20180426T1 (hr) | 2008-11-07 | 2018-03-12 | Liječenje pedijatrijske akutne limfoblastične leukemije |
| HRP20191715 HRP20191715T1 (hr) | 2008-11-07 | 2019-09-20 | Liječenje dječje akutne limfoblastične leukemije sa bispecifičnim protutijelima protiv cd3xcd19 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20110262440A1 (hr) |
| EP (4) | EP2918604B1 (hr) |
| JP (2) | JP5798036B2 (hr) |
| KR (1) | KR101695329B1 (hr) |
| CN (2) | CN106390114A (hr) |
| AU (1) | AU2009313039B2 (hr) |
| BR (1) | BRPI0921341A2 (hr) |
| CA (1) | CA2742242C (hr) |
| CY (3) | CY1116160T1 (hr) |
| DK (3) | DK2918604T3 (hr) |
| ES (3) | ES2662929T3 (hr) |
| HK (3) | HK1158667A1 (hr) |
| HR (3) | HRP20150400T1 (hr) |
| HU (3) | HUE046222T2 (hr) |
| IL (1) | IL212651A (hr) |
| LT (2) | LT2918604T (hr) |
| MX (1) | MX2011002931A (hr) |
| NO (1) | NO2918604T3 (hr) |
| NZ (1) | NZ591312A (hr) |
| PL (3) | PL2918604T3 (hr) |
| PT (3) | PT2918604T (hr) |
| RS (3) | RS53980B1 (hr) |
| RU (3) | RU2536933C2 (hr) |
| SG (1) | SG195549A1 (hr) |
| SI (3) | SI2918604T1 (hr) |
| SM (1) | SMT201500104B (hr) |
| WO (1) | WO2010052013A1 (hr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6358588A (ja) * | 1986-08-29 | 1988-03-14 | Toshiba Corp | バ−コ−ド読取装置 |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| EP2918604B1 (en) * | 2008-11-07 | 2017-12-20 | Amgen Research (Munich) GmbH | Treatment of pediatric acute lymphoblastic leukemia |
| WO2010079339A2 (en) * | 2009-01-09 | 2010-07-15 | Oxford Biomedica (Uk) Limited | Factors |
| US20150231241A1 (en) * | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| RU2678127C2 (ru) * | 2012-11-13 | 2019-01-23 | Бионтех Аг | Агенты для лечения экспрессирующих клаудин раковых заболеваний |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| CN103131777A (zh) * | 2013-02-05 | 2013-06-05 | 南京艾迪康医学检验所有限公司 | 用于检测e2a-pbx融合基因相对表达量的试剂盒 |
| US10106623B2 (en) | 2014-02-12 | 2018-10-23 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| HUE042407T2 (hu) | 2014-05-30 | 2019-06-28 | Amgen Res Munich Gmbh | B-prekurzor akut limfoblasztos leukémiában szenvedõ betegek kockázati besorolása |
| US20170252364A1 (en) | 2014-07-30 | 2017-09-07 | Mor Research Applications Ltd. | Compositions for treatment of acute lymphoblastic leukemia and methods of use thereof |
| US20170239294A1 (en) * | 2014-10-15 | 2017-08-24 | Novartis Ag | Compositions and methods for treating b-lymphoid malignancies |
| PL3221359T3 (pl) | 2014-11-17 | 2020-11-16 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia nowotworów przy użyciu dwuswoistego przeciwciała CD3XCD20 |
| EP3253408A4 (en) * | 2015-02-05 | 2018-09-26 | Stc.Unm | Anti-pre-bcr antagonists and methods |
| AU2016242866B2 (en) | 2015-03-30 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to FC gamma receptors |
| SI3280729T1 (sl) | 2015-04-08 | 2022-09-30 | Novartis Ag | Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR) |
| MX2017014731A (es) | 2015-05-20 | 2018-06-28 | Amgen Res Munich Gmbh | Eliminacion de linfocitos b como marcador diagnostico. |
| SG11201805048SA (en) * | 2015-12-22 | 2018-07-30 | Regeneron Pharma | Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia |
| GB201602974D0 (en) * | 2016-02-19 | 2016-04-06 | Clube Jasper R | Engineered cells & methods (1) |
| MA45341A (fr) * | 2016-06-06 | 2019-04-10 | Hutchinson Fred Cancer Res | Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive |
| MX2019006288A (es) | 2016-12-03 | 2020-10-01 | Juno Therapeutics Inc | Metodos y composiciones para el uso de celulas t terapeuticas en combinacion con inhibidores de quinasa. |
| MA48763A (fr) * | 2017-05-05 | 2020-04-08 | Amgen Inc | Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés |
| WO2018223101A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| KR102083481B1 (ko) | 2018-03-22 | 2020-03-02 | 강원대학교산학협력단 | 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물 |
| CA3110513A1 (en) | 2018-08-31 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
| CN113474458A (zh) * | 2019-01-30 | 2021-10-01 | 威斯塔解剖学和生物学研究所 | 靶向癌症抗原的dna编码的双特异性t细胞连接子以及在癌症治疗中的使用方法 |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| WO2021006199A1 (ja) | 2019-07-05 | 2021-01-14 | 小野薬品工業株式会社 | Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| TW202332695A (zh) | 2021-10-15 | 2023-08-16 | 德商安美基研究（慕尼黑）公司 | 結合ｃｄ１９的ｔ細胞接合劑之皮下投與 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4119397A (en) * | 1996-08-28 | 1998-03-19 | Viva Diagnostika Diagnostische Produkte Gmbh | Novel combination preparations and their use in immunodiagnosis and immunotherapy |
| NZ507381A (en) | 1998-04-21 | 2003-12-19 | Micromet Ag | CD19xCD3 specific polypeptides and uses thereof |
| AU2004242846A1 (en) * | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| BRPI0415457A (pt) * | 2003-10-16 | 2006-12-05 | Micromet Ag | constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo |
| AU2006326727A1 (en) * | 2005-12-16 | 2007-06-21 | Amgen Research (Munich) Gmbh | Means and methods for the treatment of tumorous diseases |
| PT2059536E (pt) * | 2006-08-14 | 2014-04-14 | Xencor Inc | Anticorpos otimizados que visam cd19 |
| DK2352763T4 (da) * | 2008-10-01 | 2022-10-17 | Amgen Res Munich Gmbh | Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener |
| EP2918604B1 (en) * | 2008-11-07 | 2017-12-20 | Amgen Research (Munich) GmbH | Treatment of pediatric acute lymphoblastic leukemia |
| AU2010204555B2 (en) * | 2009-01-19 | 2013-03-07 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| NZ616828A (en) * | 2009-01-19 | 2015-03-27 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8486933B2 (en) * | 2009-05-27 | 2013-07-16 | Abbvie Inc. | Pyrimidine inhibitors of kinase activity |
| NZ598461A (en) * | 2009-09-20 | 2013-12-20 | Abbvie Inc | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases |
| RS54655B2 (sr) * | 2009-10-27 | 2021-04-29 | Amgen Res Munich Gmbh | Dozni režim za primenu cd19xcd3 bispecifičnog antitela |
-
2009
- 2009-11-06 EP EP15154416.0A patent/EP2918604B1/en active Active
- 2009-11-06 US US13/127,538 patent/US20110262440A1/en not_active Abandoned
- 2009-11-06 HU HUE17206868A patent/HUE046222T2/hu unknown
- 2009-11-06 SI SI200931817T patent/SI2918604T1/en unknown
- 2009-11-06 LT LTEP15154416.0T patent/LT2918604T/lt unknown
- 2009-11-06 RS RS20150306A patent/RS53980B1/en unknown
- 2009-11-06 MX MX2011002931A patent/MX2011002931A/es active IP Right Grant
- 2009-11-06 JP JP2011533632A patent/JP5798036B2/ja active Active
- 2009-11-06 LT LTEP17206868.6T patent/LT3330293T/lt unknown
- 2009-11-06 SI SI200931185T patent/SI2344539T1/sl unknown
- 2009-11-06 SI SI200931995T patent/SI3330293T1/sl unknown
- 2009-11-06 EP EP19187179.7A patent/EP3594237A1/en active Pending
- 2009-11-06 PT PT151544160T patent/PT2918604T/pt unknown
- 2009-11-06 NO NO15154416A patent/NO2918604T3/no unknown
- 2009-11-06 BR BRPI0921341A patent/BRPI0921341A2/pt not_active Application Discontinuation
- 2009-11-06 SG SG2013076310A patent/SG195549A1/en unknown
- 2009-11-06 HU HUE09764710A patent/HUE025452T2/en unknown
- 2009-11-06 PL PL15154416T patent/PL2918604T3/pl unknown
- 2009-11-06 RU RU2011122827/10A patent/RU2536933C2/ru active
- 2009-11-06 ES ES15154416.0T patent/ES2662929T3/es active Active
- 2009-11-06 EP EP09764710.1A patent/EP2344539B1/en active Active
- 2009-11-06 CA CA2742242A patent/CA2742242C/en active Active
- 2009-11-06 NZ NZ591312A patent/NZ591312A/xx unknown
- 2009-11-06 ES ES09764710.1T patent/ES2535257T3/es active Active
- 2009-11-06 DK DK15154416.0T patent/DK2918604T3/en active
- 2009-11-06 CN CN201610281293.4A patent/CN106390114A/zh active Pending
- 2009-11-06 PL PL17206868T patent/PL3330293T3/pl unknown
- 2009-11-06 DK DK17206868.6T patent/DK3330293T3/da active
- 2009-11-06 ES ES17206868T patent/ES2748126T3/es active Active
- 2009-11-06 AU AU2009313039A patent/AU2009313039B2/en active Active
- 2009-11-06 DK DK09764710.1T patent/DK2344539T3/en active
- 2009-11-06 CN CN200980144400.7A patent/CN102209729B/zh active Active
- 2009-11-06 WO PCT/EP2009/007969 patent/WO2010052013A1/en active Application Filing
- 2009-11-06 RS RS20180309A patent/RS56989B1/sr unknown
- 2009-11-06 RS RSP20191232 patent/RS59348B1/sr unknown
- 2009-11-06 KR KR1020117010642A patent/KR101695329B1/ko active IP Right Grant
- 2009-11-06 HU HUE15154416A patent/HUE036922T2/hu unknown
- 2009-11-06 PL PL09764710T patent/PL2344539T3/pl unknown
- 2009-11-06 PT PT97647101T patent/PT2344539E/pt unknown
- 2009-11-06 PT PT172068686T patent/PT3330293T/pt unknown
- 2009-11-06 EP EP17206868.6A patent/EP3330293B1/en active Active
-
2011
- 2011-05-03 IL IL212651A patent/IL212651A/en active IP Right Grant
- 2011-12-07 HK HK11113214.0A patent/HK1158667A1/xx unknown
-
2014
- 2014-10-13 RU RU2014141180A patent/RU2677324C2/ru active
-
2015
- 2015-03-31 CY CY20151100317T patent/CY1116160T1/el unknown
- 2015-04-10 HR HRP20150400TT patent/HRP20150400T1/hr unknown
- 2015-04-27 SM SM201500104T patent/SMT201500104B/xx unknown
- 2015-08-20 JP JP2015163116A patent/JP6130451B2/ja active Active
-
2016
- 2016-03-15 HK HK16102956.0A patent/HK1215258A1/zh unknown
-
2018
- 2018-03-12 HR HRP20180426TT patent/HRP20180426T1/hr unknown
- 2018-03-14 CY CY20181100310T patent/CY1120022T1/el unknown
- 2018-11-16 HK HK18114719.1A patent/HK1255590B/zh unknown
- 2018-12-14 RU RU2018144313A patent/RU2736802C2/ru active
-
2019
- 2019-09-20 HR HRP20191715 patent/HRP20191715T1/hr unknown
- 2019-10-03 CY CY20191101035T patent/CY1122428T1/el unknown
-
2022
- 2022-09-16 US US17/932,739 patent/US20230235053A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150400T1 (hr) | Lijeäśenje pedijatrijske akutne limfoblastiäśne leukemije | |
| HRP20151168T1 (hr) | Lijeäśenje akutne limfoblastiäśne leukemije | |
| HRP20161284T1 (hr) | METODE LIJEČENJA MULTIPLOG MIJELOMA KORIŠTENJEM KOMBINIRANIH TERAPIJA TEMELJENIH NA HuLuc63 S BORTEZOMIBOM | |
| JP2012508163A5 (hr) | ||
| RS53905B1 (en) | METHODS AND TREATMENTS FOR TUMOR DISEASE | |
| JP2012508164A5 (hr) | ||
| HRP20191162T1 (hr) | Postupci liječenja ankilozantnog spondilitisa uporabom anti-il-17 protutijela | |
| Voulgari-Kokota et al. | Mesenchymal stem cells protect CNS neurons against glutamate excitotoxicity by inhibiting glutamate receptor expression and function | |
| SI2649086T1 (en) | Use of chimeric antigen receptor-modified T cells for the treatment of cancer | |
| Lee et al. | Maternal swimming during pregnancy enhances short-term memory and neurogenesis in the hippocampus of rat pups | |
| Kale et al. | The diatoms: Big significance of tiny glass houses | |
| RU2015153250A (ru) | Cd19-специфический химерный антигенный рецептор и его применения | |
| GEP20125693B (en) | Sp35 antibodies and usage thereof | |
| JP2014513088A5 (hr) | ||
| JP2009519257A5 (hr) | ||
| HRP20230861T1 (hr) | PROTUTIJELA PROTIV PEPTIDA N3pGLU AMILOIDA BETA I NJIHOVA UPOTREBA | |
| PE20210172A1 (es) | Oligonucleotidos antisentido para alfa-sinucleina y usos de los mismos | |
| Al-Khamis | The use of immune modulating drugs for the treatment of multiple sclerosis | |
| Zaghi et al. | Innate immune responses in the outcome of haploidentical hematopoietic stem cell transplantation to cure hematologic malignancies | |
| Chong et al. | Essential role of NK cells in IgG therapy for experimental autoimmune encephalomyelitis | |
| CN110038017A (zh) | 5-氨基水杨酸的新用途 | |
| Hayashi et al. | Development of the hematopoietic system: Role of inflammatory factors | |
| Zhao et al. | The potential protective role of the combination of IL-22 and TNF-α against genital tract Chlamydia trachomatis infection | |
| Kurup et al. | Glimpses into the past: New World contributions towards understanding the basic etiology, pathobiology and treatment of rabies | |
| Méndez-Maldonado et al. | Activation of Hes1 and Msx1 in transgenic mouse embryonic stem cells increases differentiation into neural crest derivatives |